 DUBLIN, Ireland, and Boston MA, July 28, 2021, Amryt Nasdaq: AMYT, AIM: AMYT, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at both of todays General Meetings were duly passed. 